NEW YORK (GenomeWeb) – Startup diagnostics firm CereDx is looking to establish rapid molecular testing to distinguish strokes from stroke mimics in a hospital setting.
Based on immune system-related biomarkers licensed from West Virginia University, the Morgantown-based firm has plans to launch a protein-based panel for point-of-care diagnostics platforms in the next two or three years.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
